CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1 competing product in clinical development for CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction.
Pipeline by Phase
Phase 21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| epirubicin + oxaliplatin + capecitabine + zolbetuximab | Astellas Pharma | Phase 2 | Completed | 35 |